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sthma affects 5% of the adult population and is 
characterized by symptoms of variable airﬂ  ow 
limitation, airway inﬂ  ammation, and airway hyperre-
sponsiveness. Polarization of the inﬂ  ammatory response 
toward increased expression of T helper 2 (Th2) 
cytokines is considered an important component of 
the asthma paradigm.    1     A major effector axis resulting 
in induction of Th2 polarization is the recognition of 
allergen presented by dendritic cells in local lymph 
nodes to CD4  1   T cell. This axis is an optimal target 
for drug development because it orchestrates inﬂ  am-
mation and the development of an allergen-speciﬁ  c 
humoral response and the development of T- and 
B-cell memory. The differentiation of naive T cells or 
reactivation of memory T cells depends on various 
costimulatory molecules expressed on the T-cell sur-
face, and their cognate ligands.    2     One of the most 
    Background:       The costimulatory molecule OX40 and its ligand, OX40L, mediate key aspects of 
allergic airway inﬂ  ammation in animal models of asthma, including eosinophilic airway inﬂ  amma-
tion, airway hyperresponsiveness, and T helper 2 polarization. We sought to examine OX40/
OX40L and interleukin (IL)-4 expression in asthma across severities. 
    Methods:       Bronchial biopsies were obtained from 27 subjects with asthma (mild Global Initiative 
for Asthma [GINA] 1 [n    5    10], moderate GINA 2-3 [n    5    7], and severe GINA 4-5 [n    5   10])  and 
13 healthy controls. The number of OX40  1  , OX40L  1  , IL-4  1  , and IL-4 receptor   a   (IL-4R  a  )  1   cells in 
the lamina propria and airway smooth muscle (ASM) bundle and the intensity of IL-4R  a    1   expres-
sion by the ASM were assessed. 
    Results:       The number of OX40  1  , OX40L  1  , and IL-4  1   cells in the lamina propria and OX40  1   and 
IL-4  1   cells in the ASM bundle was signiﬁ  cantly increased in subjects with mild asthma, but not in 
those with moderate or severe asthma, compared with healthy controls. In the subjects with 
asthma, OX40/OX40L expression was positively correlated with the number of eosinophils and 
IL-4  1   cells in the lamina propria. The number of IL-4R  a    1   cells in the lamina propria was signiﬁ  -
cantly increased in moderate-to-severe disease, but not in mild asthma, compared with controls. 
IL-4R  a   expression by the ASM bundle was not different among groups. 
    Conclusions:       OX40/OX40L expression is increased in the bronchial submucosa in mild asthma, 
but not in moderate-to-severe disease, and is related to the degree of tissue eosinophilia and IL-4 
expression. Whether these costimulatory molecules have a role as targets for asthma requires 
further investigation.     CHEST 2010; 137(4):797–804 
    Abbreviations:   ASM  5   airway smooth muscle; GINA   5   Global Initiative for Asthma; IL   5   interleukin; IL-4R a   5   IL-4 
receptor   a ;  IQR  5   interquartile range; OX40L   5   OX40 ligand; Th2   5   T helper 2; TSLP   5   thymic stromal lymphopoietin 
  Airway Wall Expression of OX40/OX40L 
and Interleukin-4 in Asthma 
  Salman    Siddiqui ,   PhD ;   Vijay    Mistry ,   BSc ;   Camille    Doe ,   MSc ;   Sally    Stinson ,   MSc ; 
 Martyn    Foster ,   PhD ;  and   Christopher    Brightling ,   PhD ,   FCCP      
  Manuscript received August 3, 2009; revision accepted December 
12, 2009. 
  Afﬁ  liations:   From the Institute of Lung Health (Drs Siddiqui 
and Brightling, Mr Mistry, and Ms Doe) University of Leicester, 
Leicester; and AstraZeneca (Ms Stinson and Dr Foster), R&D 
Charnwood, Loughborough, England    . 
  Funding/Support:   This study was supported by AstraZeneca, a 
Department of Health     Clinician Scientist award, and a Wellcome 
Senior Clinical Fellowship. 
  Correspondence to:   Christopher Brightling, PhD, FCCP, 
Institute of Lung Health, Department of Infection, Inﬂ  ammation 
and Immunity, University of Leicester, Leicester, LE3 9QP, 
England; e-mail: ceb17@le.ac.uk     798 Original Research
 Immunohistochemistry 
  Two-micrometer sections were cut and immunostained with 
the following mouse monoclonal antibodies: OX40 and OX40L 
(BD Biosciences; Oxford, England) and IL-4 (clones 4D9 and 
3H4; AMS Biotechnology; Oxford, England) and IL-4R  a   (R&D 
Systems; Abingdon, Oxfordshire, England) in quadruplicate; 
  a  -smooth muscle actin (Dako; Cambridge, England    ); and major 
basic protein (Caltag; Paiseley, England) with appropriate isotype 
controls (Dako    ). The number of positively stained nucleated cells 
was enumerated per square millimeter of the lamina propria or 
airway smooth muscle (ASM) by a blinded observer. A minimum 
ASM area of 0.1 mm  2   was considered assessable, as described pre-
viously.  14     The number of subjects with adequate smooth muscle 
was 10/13 controls, 10/10 GINA 1 asthma, 6/7 GINA 2-3 asthma, 
and 8/10 GINA 4-5 asthma. IL-4R  a   expression by the ASM was 
also assessed using a semiquantitative intensity score of no stain-
ing  5   0,  low  5   1,  moderate  5    2, and high    5   3.   Post hoc   in three 
subjects with asthma, sequential sections were stained for OX40 
and CD3 (T cells), and OX40L and CD1a (dendritic cells). The 
proportion of the OX40 or OX40L  1   cells that were colocalized to 
T cells or dendritic cells, respectively, was determined as previ-
ously described.    15   
 Analysis 
  Statistical analysis was performed using PRISM software, ver-
sion 4 (GraphPad Software; La     Jolla, CA). Parametric data were 
presented as mean (SEM) and nonparametric data as median 
(interquartile range [IQR]). Parametric data were analyzed with 
one-way analysis of variance (ANOVA) and Bonferroni’s posttest 
correction for intergroup comparison. Nonparametric data were 
analyzed using the Kruskal-Wallis tests and Dunn’s test for   post 
hoc   comparison. The Fisher exact test was used to assess the cat-
egorical differences in expression in ASM. Correlations between 
parametric data were assessed by Pearson’s correlation and non-
parametric data by Spearman’s rank correlation.   P   ,   .05 was con-
sidered signiﬁ  cant. 
 Results 
  The baseline clinical characteristics are as shown in 
    Table 1      . The subjects with asthma and the controls 
were matched for age and gender. Subjects with 
asthma had a higher BMI compared with controls, 
and evidence of airway hyperresponsiveness    . 
  Photomicrographs illustrating OX40, OX40L, IL-4, 
IL-4R  a  , and the colocalization of OX40, OX40 with 
T cells, and dendritic cells, respectively, in the lamina 
propria and their appropriate isotype controls are as 
shown (  Fig 1    ). In a subset of asthmatics (n    5   3),  we 
determined that mean (SEM) 56 (6)% of the OX40L  1  
cells in the lamina propria were dendritic cells and 
94 (6)% of the OX40  1   cells were T cells. 
  The mean (SEM) number of OX40  1   cells in the 
lamina propria was signiﬁ  cantly increased in subjects 
with mild corticosteroid-naive (GINA 1) asthma 
(1.2 [0.5]/mm  2  ), but not in those with moderate 
asthma (GINA 2-3) (0.31 [0.16]/mm  2  ) or severe 
asthma (GINA 4-5) (0.3 [0.16]/mm  2 ),  compared 
with healthy controls (0.2 [0.1]/mm  2 )  ( P   5   .048, 
promising costimulatory targets is OX40 and its 
ligand, OX40L, which has relative T-cell speciﬁ  city 
and is not expressed on naive T cells.    3   
  OX40 is primarily induced on T cells in the effector 
phase and is predominantly expressed by Th2 cells.    4   
In mouse models of allergic inﬂ  ammation,  OX40 
knockout mice have signiﬁ  cantly  reduced  Th2 
responses to allergen, accompanied by a reduction in 
airway eosinophilia and airway hyperreactivity.    5   
OX40L is expressed mainly by antigen-presenting 
cells, particularly dendritic cells,    6     but also B cells, 
macrophages, and Langerhans cells.    6     In the airway, 
dendritic cells express OX40L in response to stimula-
tion by epithelial cell-derived thymic stromal lym-
phopoietin (TSLP).    7     In murine and nonhuman 
primate models of asthma  in vivo,  blockade of OX40L 
inhibits TSLP-mediated Th2 inﬂ  ammation  and 
attenuates the number of OX40L  1   dendritic cells in 
the lung.    8     Whether OX40 and OX40L expression are 
increased in human airway tissue from subjects with 
asthma is unknown. We hypothesized that OX40 and 
OX40L expression is increased in the bronchial lam-
ina propria and that this expression is related to dis-
ease severity and Th2 cytokine expression. To test 
our hypothesis, we enumerated OX40, OX40L, inter-
leukin (IL)-4, and IL-4 receptor   a   (IL4-R a )  expres-
sion in bronchial biopsies from subjects with mild, 
moderate, and severe asthma, compared with healthy 
controls. 
  Materials and Methods 
 Subjects 
  Twenty-seven patients with asthma and 13 healthy controls 
were recruited from Glenﬁ   eld Hospital, Leicester, England. 
All subjects were nonsmokers with a smoking history of   ,  10 
pack-years, had been free of exacerbations, and were on stable 
treatment of 8 weeks prior to entry into the study. Asthma 
was deﬁ  ned by one or more of the following objective criteria: 
significant bronchodilator reversibility of   .   200 mL, a provo-
cation concentration of methacholine causing a 20% fall in 
FEV  1    ,    8 mg/mL, and/or a peak ﬂ  ow amplitude % mean over 
2 weeks of   .   20%. Asthma severity was deﬁ  ned according to the 
Global Initiative for Asthma (GINA) treatment steps.    9    Normal 
subjects had no history of respiratory disease and normal spirom-
etry. The study was approved by the Leicestershire Research 
Ethics Committee and informed consent was obtained from all 
subjects. 
  Protocol and Clinical Characterization 
  Subjects attended on two occasions. At the ﬁ   rst visit, they 
underwent spirometry; allergen skin prick tests for   Dermatopha-
goides pteronyssinus  , dog, cat and grass pollen; a methacholine 
inhalation test;    10     and sputum induction.    11     At the second visit 
1 week later, subjects underwent bronchoscopy.    12    Mucosal  biopsy 
specimens were processed into the water-soluble resin glycol 
methacrylate (Polysciences; Northampton, England) for embedding.    13   www.chestpubs.org CHEST / 137 / 4 / APRIL, 2010    799
(1.9 [0.7]/mm  2 ), but not in those with moderate asthma 
(0.17 [0.1]/mm  2  ) or severe asthma (0.51 [0.21]/mm  2 ), 
compared with healthy controls (0.55 [0.3]/mm  2 ) 
  Table 1—  Baseline Clinical Characteristics   
Control (n   5   13)
Asthma
GINA 1 (n   5   10) GINA 2-3 (n   5   7) GINA 4-5 (n   5   10)
Age (y    ) 40 (3) 45 (5) 55 (7) 49 (5)
Sex, male (female) 6 (7) 5 (5) 4 (3) 6 (4)
Atopy, % 33 50 57 67
Disease duration, y NA 12 (4) 12 (5) 17 (5)
BDP equivalent/24 h, mcg NA 0 960 (194)  a  1,092 (136)  a   OCS (n   5   2)
BMI, kg/m  2  24 (1) 32 (2) 31 (2) 30 (2)
Postbronchodilator FEV  1  % 103 (4) 95 (6) 99 (4) 83 (8)
Postbronchodilator FEV  1  /FVC, % 81 (3) 77 (4) 78 (2) 74 (3)
PC  20 , b   mg/mL   .  16 0.5 (0.1-2.2) 0.5 (0.2-1.9) 0.4 (0.1-2.1)
Bronchodilator response FEV  1  % 0.6 (1) 12 (6) 4 (3) 16 (7)
Sputum eosinophils,  b   % 0.3 (0.2-0.5) 0.7 (0.2-2.8) 1.2 (0.4-3.8) 2.6 (0.4-17)  a 
Sputum neutrophils, % 64 (20) 51 (10) 58 (9) 52 (14)
Eosinophils/mm  2   lamina propria  c  1.9 (3.7) 21.3 (34.5)  a  12.1 (12.7) 6.1 (38.4)
Data expressed as mean (SEM) unless otherwise indicated. BDP   5   beclamethasone diproprionate equivalent dose; GINA   5   Global Initiative for 
Asthma; NA   5   not applicable; OCS   5   oral corticosteroid; PC  20   5   provocation concentration causing a 20% fall in FEV  1 .
  a  P   ,  .05.
  b  Geometric mean (95% CI).
  c  Median (interquartile range).
  Figure   1. Examples of photomicrographs of immunohistochemical staining for isotype control (  A ), 
OX40 (  B  ), OX40L (  C  ), IL-4(3H4) (  D  ), IL-4(4D9) (  E ),  IL-4R a   ( F  ), and sequential sections staining for 
OX40 (  G  ), CD3 (  H  ), CD1a (  I  ) and OX40L (  J  ) (original magniﬁ  cation   3    400    ). Positive cells are high-
lighted by arrows in   B - F  . In   G   and   I  , positive cells are highlighted by arrows and the corresponding cell 
if positive in   H   and   J .  IL  5   interleukin; IL-4R a   5   IL-4 receptor   a ;  OX40L  5   OX40  ligand  .   
A  B  C 
D  E  F 
G  H 
I  J 
ANOVA;   P   ,   .05, control vs GINA 1) (  Fig 2  A   ).  Similarly, 
the number of OX40L  1   cells in the lamina propria was 
signiﬁ  cantly increased in subjects with mild asthma 800 Original Research
(  P   5   .04, ANOVA;   P   ,   .05, control vs GINA 1) (  Fig 2  B  ) .  
The median (IQR) number of OX40  1   cells in the 
ASM bundle was not signiﬁ  cantly different across the 
groups (  P   5    .08, Kruskal-Wallis), but the propor-
tion of patients with OX40  1   cells in the ASM was 
signiﬁ  cantly increased in mild asthma (5/10), but not 
in moderate (1/6) or severe asthma (3/8), compared 
with the controls (0/10) (  P   5    .03, Fisher exact test) 
 (Fig  2 C  ).  OX40L 1   cells were not identiﬁ  ed within the 
ASM bundle in health or asthma. There was a strong 
correlation between the number of OX40 and OX40L  1  
cells in the lamina propria (r    5   0.83;   P   ,  .0001) 
( Fig  2 D  ). 
  The mean (SEM) number of IL-4 (3H4)  1   cells in 
the lamina propria was signiﬁ  cantly increased in sub-
jects with mild asthma (2.7 [1.0]/mm  2  ), but not in 
those with moderate asthma (0.64 [0.4]/mm  2 )  or 
severe asthma (0.84 [0.25]/mm  2  ), compared with 
healthy controls (0.26 [0.15]/mm  2 )  ( P   5   .01, ANOVA; 
  P   ,    .01, control vs GINA 1) (  Fig 3  A   ).  Similarly,  the 
number of IL-4 (4D9)  1   cells in the lamina propria 
was signiﬁ   cantly increased in subjects with mild 
asthma (3.4 [1.4]/mm  2  ), but not in those with moder-
ate asthma (0.61 [0.23]/mm  2  ) or severe asthma 
(0.45 [0.2]/mm  2  ), compared with healthy controls 
(0.17 [0.09]/mm  2 )  ( P   5    .007, ANOVA;   P   ,  .01,  con-
trol vs GINA 1) (  Fig 3  B    ). The median (IQR) number 
of IL-4  1   (3H4 and 4D9) cells in the ASM bundle was 
signiﬁ  cantly increased in subjects with mild asthma 
(0.5 [10.8] and 1.2 [6.8]/mm  2  ), but not in those with 
moderate asthma (0 [0.5] and 0 [0.8]/mm  2  ) or severe 
asthma (0 [0] and 0 [0]/mm  2  ), compared with healthy 
controls (0 [0] and 0 [0]/mm  2 )  ( P   5   .04 and   P   5   .027, 
Kruskal-Wallis) (  Figs 3  C ,   D  ). 
  In contrast, the mean (SEM) number of IL-4R  a  1  
cells in the lamina propria was increased in moder-
ate asthma (3.2 [0.9] cells/mm  2  ) and severe asthma 
(3.1 [0.5] cells/mm  2  ), but not in mild disease 
(1.9 [0.5] cells/mm  2  ), compared with healthy con-
trols (  P   5    .002, ANOVA) (  Fig 4  A      ). The intensity of 
IL-4R  a   expression by ASM was not signiﬁ  cantly 
different between asthma and healthy controls (  P   5   .3, 
ANOVA) (  Fig 4  B  ). 
  In the subjects with asthma, OX40 and OX40L 
expression in the lamina propria was strongly correlated 
with the IL-4 (3H4) (r   5   0.67,  P   ,   .0001 and r   5   0.59, 
  P   5    .001) and (4D9) (r    5   0.48,   P   5    .01 and r    5   0.4, 
  P   5   .038) expression, respectively (  Fig 5    ). The num-
ber of OX40  1   cells in the ASM bundle was not signiﬁ  -
cantly correlated with the number of IL-4  1   (3H4 or 
4D9) cells (data not shown). We also observed a 
strong correlation between the number of OX40L  1  
cells and eosinophils in the lamina propria (rs   5   0.64, 
  P   ,   .0001), but not with OX40/IL-4 expression (data 
not shown). There were no signiﬁ  cant correlations 
among OX40, OX40L, or IL-4 expression in the lamina 
  Figure   2. The number of OX40    1    (  A  ) and OX40L  1   cells (  B  ) in the 
lamina propria and OX40  1   cells (  C  ) in the ASM bundle in subjects 
with asthma and healthy controls. The correlation between OX40 
and OX40L expression in the lamina propria (  D ).      5   controls; 
  l   5   GINA 1;     5   GINA 2;     5   GINA 3;     5   GINA 4; X  5   GINA 5. 
*  P   ,  .05. ASM  5   airway smooth muscle; GINA   5   Global Initiative 
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 Discussion 
 We report here, to our knowledge for the ﬁ  rst time, 
that the number of OX40  1   and OX40L  1   cells are 
increased in the lamina propria and OX40  1   cells  in the 
ASM bundle in mild asthma, but not in moderate-to-
severe disease. OX40L  1   cells were not observed in 
the ASM bundle in health or disease. The number of 
OX40/OX40L cells in the lamina propria was associated 
with IL-4 expression and eosinophilic inﬂ  ammation. 
  To date, there have been no reports of OX40 or 
OX40L expression in bronchial submucosal tissue in 
asthma. Therefore, our observation that OX40 and 
OX40L expression is increased in mild asthma pro-
vides further evidence of a potential role of these 
molecules in asthma. We     identiﬁ  ed that the majority 
of OX40  1   cells were T cells and OX40  L1   cells  were 
dendritic cells. Previously, animal studies have impli-
cated these costimulatory molecules in the immu-
nopathogenesis of asthma. In mouse models of allergic 
inﬂ  ammation, OX40 knockout mice have signiﬁ  cantly 
reduced Th2 responses to allergen with a reduction 
in airway eosinophilia and airway hyperreactivity.    5,16,17   
Dendritic cell-derived OX40L is induced by TSLP, 
a IL-7-like cytokine produced by epithelial cells, 
propria or ASM bundle and FEV  1  % predicted, bron-
chodilator response, or airway hyperresponsiveness 
(data not shown). 
  Figure   4. The number of IL-4R  a  1   cells in the lamina propria (  A ) 
and IL-4R  a   expression by the ASM bundle (  B  ) in subjects with 
asthma and healthy controls. See Figures 1 and 2 legends for 
expansion of abbreviations.      5   controls;  l   5   GINA 1;      5   GINA 2; 




  Figure   3. The number of IL-4 (3H4)  1   cells (  A  ) and IL-4 (4D9)  1  
cells (  B  ) in the lamina propria and IL-4 (3H4)  1   cells (  C  ) and IL-4 
(4D9)  1   cells (  D  ) in the ASM bundle in subjects with asthma and 
healthy controls.      5   controls;   l   5    GINA 1;      5   GINA  2; 
     5   GINA 3;      5   GINA 4; X   5   GINA 5. *  P   ,   .05. See Figure 1 





mast cells located within the ASM bundle    14,28    are  an 
important source of tumor necrosis factor-  a   29    and 
following activation may induce ASM-derived OX40L. 
ASM cells have established contractile and synthetic 
function and to this may be added a possible immu-
nomodulatory role. Therefore, the role of mesen-
chymal cells and their interactions with inﬂ  ammatory 
cells in the OX40/OX40L axis need to be investi-
gated further. 
  Importantly, we were unable to demonstrate 
increased OX40/OX40L expression in moderate-to-
severe disease, in contrast to mild asthma. This may 
reﬂ  ect real differences among disease severities, per-
haps as a consequence of treatment. Importantly, the 
number of subjects included in this study was rela-
tively small and therefore our inability to demonstrate 
an increase in moderate-to-severe disease may be 
  because of inadequate powering of the study. Fur-
thermore, we may have underestimated OX40 and 
OX40L expression in asthma, because it may be tran-
sient and may increase in response to activation such 
as allergen challenge. Similarly, the potential beneﬁ  ts 
of therapeutic blockade of OX40/OX40L may depend 
on sensitization and the duration of post-allergen 
challenge. In mouse models of asthma, conﬂ  icting 
data exist regarding the most efﬁ  cacious time point to 
neutralize OX40L, with one report suggesting that 
presensitization alone, and not subsequent challenge, 
led to a reduction in the asthmatic response,    17    and 
another ﬁ  nding that airway inﬂ  ammation was attenu-
ated in postsensitized animals.    30    Therefore,  although 
our inability to demonstrate increased expression 
which provides an important interaction between 
the epithelial-dendritic cell.   7   Critically, OX40L neutral-
ization in mouse and nonhuman primate models of 
asthma inhibited TSLP-induced immune responses, 
including Th2 inﬂ  ammatory cell inﬁ  ltration, cytokine 
secretion, and IgE production   8  . Consistent with these 
observations, our ﬁ  ndings showed a close association 
between the number of eosinophils and IL-4 expression 
in the lamina propria and the OX40/OX40L axis. 
However, in contrast to the animal models, a rela-
tionship was not indicated between OX40/OX40L 
expression and disordered airway physiology, includ-
ing airway hyperresponsiveness. This dissociation 
between airway function and Th2-mediated eosino-
philic inﬂ  ammation is consistent with observations 
made in noneosinophilic bronchitis   18,19   and the response 
to highly speciﬁ  c anti-IL-5 therapy.    20,21    These  obser-
vations in human disease may challenge a potential 
role for the OX40/OX40L axis in airway dysfunction 
in asthma and need to be examined further. 
  Interestingly, OX40L expression by dendritic 
cells is also increased by environmental fungal    22    and 
endotoxin  23     exposure, which have both been impli-
cated in asthma and asthma exacerbations.    24,25   
OX40L production is also not restricted to dendritic 
cells, because other cells such as ASM may be 
important potential sources.    26,27     Ex vivo   data in 
human ASM cells have shown that OX40/OX40L 
expression was upregulated by tumor necrosis 
factor-  a  , and, interestingly, was signiﬁ  cantly greater 
in asthmatic vs nonasthmatic ASM cells. We did 
not observe OX40/OX40L expression by ASM, but 
  Figure   5. The correlations between OX40/OX40L and IL-4 expression in the lamina propria. See 
Figure 1 legend for expansion of abbreviations.     
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  In keeping with the OX40/OX40L expression, IL-4 
upregulation was restricted to those subjects with 
mild disease. This is consistent with an earlier 
report,  31     but is in stark contrast to IL-13 expression, 
which resulted in an increase in the sputum and 
bronchial mucosa of severe asthmatics.    32,33    Interest-
ingly, the number of IL-4R  a  1   cells was increased in 
the lamina propria in moderate-to-severe disease, 
with a small, nonsigniﬁ  cant increase in mild asthmat-
ics. This differential expression of IL-4 and IL-13 in 
severe disease has important implications for poten-
tial therapeutic strategies in severe asthma directed 
toward either cytokine neutralization    34,35    or  receptor 
antagonism.  36     In addition, the balance between the 
expression of cytokines and their receptors in severe 
disease is likely to be clinically important and requires 
further consideration. 
 Conclusions 
  In conclusion, we have shown that the OX40/
OX40L axis is upregulated in mild asthma. But not 
in moderate-tosevere disease, and is related to the 
intensity of IL-4 expression and eosinophilic inﬂ  am-
mation. Whether these costimulatory molecules pres-
ent new therapeutic targets for asthma, and how we 
can determine which severity of asthma and what 
stage of the natural history of disease may beneﬁ  t, 
require further investigation. 
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